Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347159 · ClinicalTrials.gov registry record · Phase 2

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

A Phase 2 study of Hypertrophic Cardiomyopathy, sponsored by Edgewise Therapeutics.

Active
Registry status
Phase 2
Development phase
100
Enrollment target
20
Study locations

NCT06347159: Active Phase 2 study of Hypertrophic Cardiomyopathy, sponsored by Edgewise Therapeutics.

NCT06347159 is a Phase 2 study of Hypertrophic Cardiomyopathy that is active but no longer recruiting, run by Edgewise Therapeutics. The registered enrollment target is 100 participants, below the 1,341-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347159, a Phase 2 study of Hypertrophic Cardiomyopathy, is active but no longer recruiting, sponsored by Edgewise Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

Conditions Studied

Hypertrophic Cardiomyopathy

Interventions

  • DRUG EDG-7500

Study Locations (20)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Womens Hospital - Boston
  • Lahey Hospital and Medical Center - Burlington

Ohio

  • The Lindner Research Center at Christ Hospital - Cincinnati
  • University Hospitals Cleveland Medical Center - Cleveland
  • Cleveland Clinic - Cleveland

California

  • University of California, San Francisco - San Francisco
  • Stanford University Hospital / Stanford Health Care - Stanford

New York

  • North Shore University Hospital - Manhasset
  • NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only) - New York

North Carolina

  • Sanger Heart and Vascular Institute - Charlotte
  • Duke Health Center Arringdon - Morrisville

Georgia

  • Emory Clinic - Atlanta

Michigan

  • Michigan Medicine - Michigan Clinical Research Unit - Ann Arbor

Missouri

  • Saint Luke's Hospital of Kansas City - Kansas City

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-04-11
Est. Completion 2026-12
Phase Phase 2
Edgewise Therapeutics

15 total trials

What the registry record for NCT06347159 still lists

NCT06347159 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,341-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which EDG-7500 is the first listed.

NCT06347159 names 20 study sites across 13 states, led by Massachusetts, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT06347159 about?

NCT06347159 is a clinical study titled "A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)". This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

What is the current status of trial NCT06347159?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-04-11. Estimated completion is 2026-12.

What conditions does trial NCT06347159 study?

This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy.

What interventions are being tested in trial NCT06347159?

The interventions under investigation include: EDG-7500 (DRUG).

Who is sponsoring clinical trial NCT06347159?

This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347159 being conducted?

This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertrophic Cardiomyopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06347159's enrollment target sits among peer trials

100 8th of 10 higher than 3 of 10 other Hypertrophic Cardiomyopathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertrophic Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06347159, the US trial registry maintained by the National Library of Medicine. NCT06347159 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.